BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women - Related Studies

BufferGel and PRO 2000/5: Vaginal Gels to Prevent HIV Infection in Women

This study is ongoing, but not recruiting participants.

Study NCT00074425. Last updated on September 11, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Communicable Diseases
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		BufferGel
		PRO 2000/5 Gel
		Placebo gel

5	Sponsors listed in this trial
		National Institute of Allergy and Infectious Diseases (NIAID)
		Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
		National Institute on Drug Abuse (NIDA)
		National Institute of Mental Health (NIMH)
		HIV Prevention Trials Network